These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 35188949)

  • 1. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bétrisey S; Haller ML; Efthimiou O; Speierer A; Del Giovane C; Moutzouri E; Blum MR; Aujesky D; Rodondi N; Gencer B
    J Am Heart Assoc; 2024 Feb; 13(4):e030714. PubMed ID: 38323514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
    Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
    JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS
    JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
    J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
    Zhang XL; Lan RF; Zhang XW; Xu W; Wang L; Kang LN; Xu B
    J Am Heart Assoc; 2019 Aug; 8(16):e012428. PubMed ID: 31411090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
    Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
    BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
    Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial.
    Lv X; Liu X; Peng Y; Li W; Wang J; Chen X; Lei J; Tang C; Luo S; Mai W; Cai Y; Fan Q; Liu C; Zhang L
    J Stroke Cerebrovasc Dis; 2024 May; 33(5):107647. PubMed ID: 38431112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression.
    Hsu CY; Saver JL; Ovbiagele B; Wu YL; Cheng CY; Lee M
    JAMA Neurol; 2023 May; 80(5):506-515. PubMed ID: 36939729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
    Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
    Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
    Sawant S; Wang N
    Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.
    Byrne P; Demasi M; Jones M; Smith SM; O'Brien KK; DuBroff R
    JAMA Intern Med; 2022 May; 182(5):474-481. PubMed ID: 35285850
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 48.